Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Parenteral fish oil versus soybean oil in Crohn's disease with high inherent TNF-alpha production
NL-OMON40244Phase 2Recruiting
- Sponsor
- Radboud University Medical Center
- Start
- Nov 2013
- Modality
- Small Molecules, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of eicosapentaenoic acid + docosahexaenoic acid and Intralipid 10% in Crohn's disease (2 arms), sponsored by Radboud University Medical Center. Primary endpoint: Change in ex vivo TNF-alpha production by LPS-stimulated PBMCs. Started Nov 2013; status: recruiting.
02
Drugs
eicosapentaenoic acid + docosahexaenoic acidIntralipid 10%
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NL-OMON40244.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40244.